Production enhancement of the glycopeptide antibiotic A40926 by an engineered Nonomuraea gerenzanensis strain

Abstract

To improve the production of A40926, a combined strategy of constructing the engineered strain and optimizing the medium was implemented. The engineered strain lcu1 with the genetic features of dbv23 deletion and dbv3-dbv20 coexpression increased by 30.6% in the production of A40926, compared to the original strain. In addition, a combined medium called M9 was designed to be further optimized by the central composite design method. The optimized M9 medium was verified to significantly improve the A40926 yield from 257 to 332mgl-1. The engineered strain lcu1 could significantly promote A40926 production in the optimized M9 medium, which indicated that the polygenic genetic manipulation and the media optimization played an equally important role in increasing the A40926 yield.